Lu AF88434
Alternative Names: [11C]-Lu AF88434; [14C]-radiolabelled Lu AF88434; Lu AF88434Latest Information Update: 28 Sep 2023
At a glance
- Originator Lundbeck A/S
- Class Nootropics
- Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in United Kingdom (PO, Liquid)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in Netherlands (PO, Liquid)
- 21 Oct 2020 Lundbeck completed a phase I trials in Cognition disorders (In volunteers) in United Kingdom (PO) (NCT04538014)